OPC-61815 clinical trials
How each study uses OPC-61815 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Otsuka Pharmaceutical Co., Ltd. (4) · Otsuka Beijing Research Institute (1)
Studies
Open first, then newest update. How each study uses OPC-61815 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- OPC-61815 in Healthy Chinese Male SubjectsCompletedPhase 1Otsuka Beijing Research InstituteNCT05439148Written as OPC-61815 injection
- Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral IntakeCompletedPhase 3Otsuka Pharmaceutical Co., Ltd.NCT03962101Written as OPC-61815 injection
- Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart FailureCompletedPhase 3Otsuka Pharmaceutical Co., Ltd.NCT03772041Written as OPC-61815
- Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart FailureCompletedNot applicableOtsuka Pharmaceutical Co., Ltd.NCT03254108Written as OPC-61815 injection 2mg
- Phase I Study of OPC-61815CompletedPhase 1Otsuka Pharmaceutical Co., Ltd.NCT03510663Written as OPC-61815 16mg